Background and purpose A dose‐dependent association between the use of cyproterone
acetate (CPA) and intracranial meningioma has been identified but data for other potent …

Objective To assess the risk of intracranial meningioma associated with the use of selected
progestogens. Design National case-control study. Setting French National Health Data …

Purpose To report the results of systematic meningioma screening program implemented by
French authorities in patients exposed to progestin therapies (cyproterone (CPA) …

Objective To assess the risk of meningioma associated with use of high dose cyproterone
acetate, a progestogen indicated for clinical hyperandrogenism. Design Observational …

Objective The aim of this study was to describe progestin-associated meningiomas'
characteristics, outcome and management. Material and methods We included 53 patients …

Purpose Meningiomas are the most common intracranial tumors, accounting for 20–30% of
central nervous system tumors. Recently, the European Medicines Agency issued an alert …

Background The relationship between increased meningioma incidence and growth and
long-term hormonal therapy with cyproterone acetate (CPA) in women has been recently …

Meningiomas are common intracranial tumors with a female predominance. Their etiology is
still poorly documented. The role of sexual hormones has long been evoked, and data have …

The influence of exposure to hormonal treatments, particularly cyproterone acetate (CPA),
has been posited to contribute to the growth of meningiomas. Given the widespread use of …

Background The study the characteristics of surgical meningiomas in female patients who
took CPA and to compare this population to a non-CPA control group. Materials and …